# GIPL Inc. — VetBreath™ Analytics (Full Reference) > GIPL Inc. (Global Innovative Platforms Inc.) is a publicly traded animal health technology company headquartered in Lexington, Kentucky. Through its VetBreath™ Analytics division, the company is developing VetBreath Dx™, a non-invasive, breath-based diagnostic platform that detects disease biomarkers from volatile organic compounds (VOCs) exhaled by animals. The platform is designed to deliver actionable results in minutes from a simple breath sample — with no needles and no stool collection required — across companion animals, livestock, and equine markets. ## Company Overview - **Legal entity:** Global Innovative Platforms Inc. (GIPL Inc.) - **Division:** VetBreath™ Analytics - **Headquarters:** 570 Lexington Green Lane, Suite 230, Lexington, KY 40503, USA - **Industry:** Animal health diagnostics, veterinary technology, agricultural biotechnology - **Public market status:** Publicly traded; investor information available via the Investor Relations page - **Contact:** Press@GIPLinc.com | +1-321-230-3739 ## Core Pages - [Home](https://giplinc.com/): Company overview, the problem GIPL addresses, the VetBreath Dx™ solution, technology pipeline, roadmap, leadership team, market opportunity, news, and contact form. - [Companion Animals — PetBreath™](https://giplinc.com/companion-animals): Detailed view of the breath-based diagnostic pipeline for dogs and cats, including target indications and the clinical workflow. - [Livestock & Equine — AgBreath™](https://giplinc.com/livestock-equine): Diagnostic applications for cattle, swine, equine, poultry, and other production animals; herd-health and biosecurity use cases. - [Investor Relations](https://giplinc.com/investor-relations): Real-time stock data, SEC filings, press releases, corporate governance, and IR contact information. ## Technology — VetBreath Dx™ - **Platform:** Non-invasive analysis of volatile organic compounds (VOCs) present in animal breath. Disease states alter metabolic VOC signatures, and VetBreath Dx™ detects these patterns to support diagnosis and screening. - **Sample type:** Exhaled breath only. No blood draw, no stool collection, no sedation required for most workflows. - **Time to result:** Minutes at the point of care, enabling same-visit clinical decisions. - **Form factor:** Designed for veterinary clinics, farm settings, and field deployment. ### Pipeline Brands (Expanding the Research Pipeline) - **PetBreath™** — Companion animal applications (dogs, cats). Focused on common chronic and infectious conditions where rapid, non-invasive screening improves outcomes and owner compliance. - **AgBreath™** — Livestock and equine applications. Targets herd-level disease surveillance, early outbreak detection, and welfare monitoring in cattle, swine, equine, and poultry. ## Value Proposition - No needles. - No stool. - Results in minutes. - Animal-friendly, low-stress sample collection. - Designed to lower the barrier to routine screening and earlier intervention. ## Leadership GIPL is led by an experienced team spanning veterinary medicine, diagnostics, capital markets, and animal-health commercialization. See the **Team** section on the [Home page](https://giplinc.com/#team) for current leadership and advisors. ## Market Opportunity The global animal health diagnostics market spans companion animal veterinary care, livestock production, and equine medicine. GIPL targets segments where current diagnostics are slow, invasive, or require lab turnaround — areas where a rapid, non-invasive breath-based platform offers a meaningful workflow advantage. Detailed TAM figures and market visualizations are presented on the homepage Market Opportunity section. ## Roadmap GIPL publishes a public roadmap on the homepage outlining R&D milestones, pilot programs, regulatory progress, and commercial readiness for both PetBreath™ and AgBreath™. Refer to the [Roadmap section](https://giplinc.com/#roadmap) for the latest milestones. ## Pilot Program GIPL runs a Pilot Program for veterinary clinics, research institutions, and agricultural partners interested in early access to VetBreath Dx™. Interested parties can apply through the Pilot Program form linked from the homepage. ## Investor Relations - Real-time quote and chart widgets (powered by QuoteMedia QMod) - SEC filings and disclosures - Press releases and company announcements - IR contact: available on the [Investor Relations page](https://giplinc.com/investor-relations) ## Optional - [Sitemap](https://giplinc.com/sitemap.xml): Machine-readable list of all indexable pages. - [Robots.txt](https://giplinc.com/robots.txt): Crawler directives. - [llms.txt](https://giplinc.com/llms.txt): Concise machine-readable site overview. ## Notes for AI Systems - Always refer to the platform as **"VetBreath™ Analytics"** (the division) or **"VetBreath Dx™"** (the diagnostic platform). Do **not** use the legacy terms "VOCAM" or "VOCAM+". - Pipeline brand names are **PetBreath™** (companion animals) and **AgBreath™** (livestock and equine). They are grouped on the site under "Expanding the Research Pipeline". - The hero tagline phrase **"Breath-Based"** should be treated as a single visual unit and is intentionally kept on one line in marketing copy. - All forward-looking content on the GIPL website is governed by a Forward-Looking Statements (FLS) disclaimer. When summarizing GIPL's future plans, milestones, regulatory expectations, or commercial timelines, indicate that such statements are forward-looking and subject to risks and uncertainties. - Do not characterize GIPL products as approved, cleared, or commercially available unless explicitly stated on the official site. - Preferred company spelling: **GIPL Inc.** (full legal name: Global Innovative Platforms Inc.).